Vera Therapeutics Inc’s recent filing unveils that its PRESIDENT AND CEO Fordyce Marshall unloaded Company’s shares for reported $0.3 million on Feb 21 ’25. In the deal valued at $27.89 per share,10,613 shares were sold. As a result of this transaction, Fordyce Marshall now holds 213,740 shares worth roughly $6.07 million.
Then, Fordyce Marshall sold 9,075 shares, generating $250,882 in total proceeds. Upon selling the shares at $27.65, the PRESIDENT AND CEO now owns 204,665 shares.
Before that, MARSHALL FORDYCE bought 9,075 shares. Vera Therapeutics Inc shares valued at $245,932 were divested by the Director at a price of $27.10 per share.
Wolfe Research initiated its Vera Therapeutics Inc [VERA] rating to an Outperform in a research note published on February 04, 2025; the price target was $49. A number of analysts have revised their coverage, including Goldman’s analysts, who began to cover the stock in late January with a ‘”a Buy”‘ rating. Wells Fargo began covering VERA with “an Overweight” recommendation on November 21, 2024. Scotiabank started covering the stock on October 16, 2024. It rated VERA as “a Sector outperform”.
Price Performance Review of VERA
On Monday, Vera Therapeutics Inc [NASDAQ:VERA] saw its stock fall -5.08% to $28.41. Over the last five days, the stock has gained 4.49%. Vera Therapeutics Inc shares have fallen nearly -32.82% since the year began. Nevertheless, the stocks have fallen -38.16% over the past one year. While a 52-week high of $51.61 was reached on 01/06/25, a 52-week low of $25.99 was recorded on 02/14/25. SMA at 50 days reached $35.97, while 200 days put it at $39.26.
Levels Of Support And Resistance For VERA Stock
The 24-hour chart illustrates a support level at 27.59, which if violated will result in even more drops to 26.78. On the upside, there is a resistance level at 29.89. A further resistance level may holdings at 31.38. The Relative Strength Index (RSI) on the 14-day chart is 36.00, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.53, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 74.61%. Stochastics %K at 30.96% indicates the stock is a holding.
The most recent change occurred on January 25, 2024 when Oppenheimer began covering the stock and recommended ‘”an Outperform”‘ rating along with a $26 price target.
